Combination of bempedoic acid and ezetimibe

Pre-clinicalRecruiting
2 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Hypercholesterolaemia

Conditions

Primary Hypercholesterolaemia, Mixed Dyslipidemia

Trial Timeline

Jan 30, 2026 → Mar 1, 2029

About Combination of bempedoic acid and ezetimibe

Combination of bempedoic acid and ezetimibe is a pre-clinical stage product being developed by Daiichi Sankyo for Primary Hypercholesterolaemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07206472. Target conditions include Primary Hypercholesterolaemia, Mixed Dyslipidemia.

What happened to similar drugs?

20 of 20 similar drugs in Primary Hypercholesterolaemia were approved

Approved (20) Terminated (6) Active (0)
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
Duloxetine + PlaceboEli LillyApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07206472Pre-clinicalRecruiting

Competing Products

20 competing products in Primary Hypercholesterolaemia

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
40